Company / Cash & Equivalents
SOLENO THERAPEUTICS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$70.1M
FY2025
5-year range
$14.6M / $169.7M
FY2021-FY2025
Trend
-20.3%
vs FY2024
Sector context
#169 of 209
Health Care
What the data says
SOLENO THERAPEUTICS INC's cash & equivalents of $70M is lower than 81% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $3M in FY2016 to $170M in FY2023.
Based on SEC 10-K filings.
$70M in FY2025 with a 5-year CAGR of +7.3%.
Declined from $170M to $70M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +68.7%
- 5-Year CAGR
- +7.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 209This company $70.1M Sector average $696.0M
▼
-89.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.3%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 20.3% year-over-year.
- Ranks #169 out of 209 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $70.1M | -20.3% |
| FY2024 | $87.9M | -48.2% |
| FY2023 | $169.7M | +1062.0% |
| FY2022 | $14.6M | -31.5% |
| FY2021 | $21.3M | -56.7% |
| FY2020 | $49.2M | +137.4% |
| FY2019 | $20.7M | -10.2% |
| FY2018 | $23.1M | +35.1% |
| FY2017 | $17.1M | +527.3% |
| FY2016 | $2.7M | -50.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026